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Abstract: This article discusses the history of domestic penicillin production in China during 
the Second Sino-Japanese War, focusing on the work of the National Epidemic Prevention 
Bureau (NEPB) to identify, isolate, cultivate, and extract the drug. This work took place just 
as the American Bureau for Medical Aid to China discussed plans to establish an American 
pilot plant for Chinese penicillin manufacture, which would directly transfer technologies and 
personnel from the United States to China. While American advisers saw the basic conditions 
of wartime China as actively obstructing the highly technical project of penicillin production, 
researchers at the NEPB relied crucially upon that same local environment to identify useful 
molds and find substitutions for key materials in successfully manufacturing penicillin in 
Kunming, capital of Yunnan Province in southwest China.  
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On December 14, 1945, a one-year-old infant with the initials YTM was admitted to 
the Shanghai Public Hospital for Children. The boy had had a fever and cough for over two 
weeks, and initial treatment with sulfonamides—the first antibiotics and global wonder drugs 
of the 1940s—had resolved the former complaint, but not the latter. Upon his admission to 
hospital, physical examination revealed “a child, fairly well-developed, under-nourished, 
dyspneic [having difficulty breathing] and cyanotic [with skin tinged blue due to tissues near 
the skin surface having low oxygen saturation].” The child’s chest bulged on the left side, and 
examination with X-ray methods of fluoroscopy revealed that this was due to fluid in the 
tissues. A procedure to remove fluid from the lungs produced 150 cubic centimeters of “thick 
pus” that tested positive for pneumococcus, the bacterium that causes pneumonia.1  
Before December 1945, such cases of empyema, or fluid in the pleural cavity typically 
due to pneumonic infection, were often mortal for young patients. The only available 
treatment consisted of surgical interventions with such high levels of risk that many surgeons 
                                                
1 Lin Shujin, “Penicillin in the Treatment of Empyema,” 74. The case study is described as commencing on 
December 14, 1946, but since the article was published in March/April 1946, the note must be an error and 
actually refers to 1945. The other cases described all happened in December 1945 and January 1946.  
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were not willing to attempt them on children. But in April 1946, Lin Shujin, resident 
physician at the Shanghai Public Hospital for Children, gave a paper to the Chinese Pediatric 
Society and the Chinese Medical Association that revealed a chemotherapeutic alternative. 
Five days after the young YTM was admitted to hospital, he was given penicillin (qingmeisu, 
or alternatively pannixilin). After a combination of intrapleural and intramuscular 
administration totalling 580,000 Oxford units of penicillin for ten days, “the patient’s general 
condition improved markedly during treatment.”2 After discussing a number of other similar 
case studies, Lin concluded that compared with surgical interventions or treatment with 
sulfonamides, “penicillin therapy is definitely superior for the treatment of empyema in 
pediatric practice.”3 
This paper was just one of the many studies that emerged at the end of the Second 
Sino-Japanese War which discussed the potential of penicillin, a drug produced from the 
fungus Penicillium notatum, as a therapeutic agent in glowing terms. The medicine’s potential 
was all the more exciting given the catastrophe that epidemic disease had wrought during the 
war years. By 1938, just one year after the outbreak of conflict with Japan, cholera had 
ravaged Hubei, Hunan, and Jiangxi Provinces, and relapsing fever had spread across 
northwest China. The malarial diseases traditionally associated with southern and 
southwestern China also reared their heads in those regions.4 In 1939 the plague struck 
Yunnan, and in 1942 a cholera outbreak ravaged the province. Wartime migrations of soldiers 
and refugees only facilitated the spread of such diseases across China’s interior.5 In 1943 Jin 
Baoshan, the wartime head of the National Health Administration (Weishengshu), noted that 
plague and cholera were the most serious epidemic threats facing the nation, and “under war 
                                                
2 Lin Shujin, “Penicillin in the Treatment of Empyema,” 75. An Oxford unit of penicillin referred to a standard 
unit of potency for the drug, as defined by its ability to prevent the growth of the bacterium Staphylococcus 
aureus, and calibrated against samples of penicillin distributed from the Oxford laboratory where the standard 
had been developed.   
3 Lin Shujin, “Penicillin in the Treatment of Empyema,” 84. 
4 Yip, “Disease and the Fighting Men,” 174; Bello, “To Go Where No Han Could Go.”  
5 Yip, “Disease and the Fighting Men,” 174. 
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conditions there have been serious outbreaks of typhus fever and relapsing fever among the 
soldiers and refugees.”6 In such dire conditions, the promise of a drug like penicillin that 
could quickly resolve a variety of infections was a godsend. 
Lin did not discuss the source of the drug used at Shanghai Public Hospital for 
Children. Yet the establishment of penicillin as a therapeutic drug in China was a remarkable 
event, one with origins in the Second Sino-Japanese War that had concluded just a year 
earlier. The first drugs arrived in China from the United States in August 1944 as a result of 
the Lend-Lease Act, the American program to support Allied nations by sending them 
material aid in the form of food, weapons, fuel, and other items necessary for the machinery 
of war.7 The regular domestic production of penicillin in China, by Chinese bacteriologists, 
was another matter altogether. It relied on the wartime work of a small unit with temporary 
headquarters in remote Yunnan province, the National Epidemic Prevention Bureau (NEPB).  
This article discusses the history of domestic penicillin production in China, focusing 
on the wartime efforts of the NEPB in Kunming to isolate antibacterial mold strains and 
develop them as viable therapeutic drugs despite a number of logistical and theoretical 
challenges. In contrast to narratives that place American institutions, tools, and people at the 
center of global histories of penicillin manufacture, Tang Feifan and the NEPB developed the 
capacity to produce small amounts of penicillin without access to the equipment, raw 
materials, or strains that were thought to be necessary to such a project. The establishment of 
penicillin in China might seem at first blush to be anything but ordinary, given that its agents 
have been praised as pioneers of medical science who inaugurated a new age of 
pharmaceutical development in China.8 Their work indeed laid the foundations for penicillin 
to become a significant and widely used drug in China. Over subsequent decades, its 
                                                
6 King, “Epidemic Prevention and Control in China,” 51. 
7 Preliminary Report of the Central Penicillin Control Committee with Special Reference to the Activities of the 
Subcommittee for Civilians, January 25, 1945, p. 1, Archives of the American Bureau for Medical Aid to China, 
box 24. 
8 Xu Dingding, “Kangri zhanzheng shiqi,” 357. 
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employment became so common that antibiotic-resistant bacteria now pose a major threat to 
public health in East Asia. Moreover, negotiations in the 1940s over how to transfer 
technologies of penicillin production from the United States to China revealed tensions over 
the conditions of normal, everyday life in China—and the extent to which these conditions 
were not considered to be compatible with the technologically complex production of 
penicillin.  
Exchanges between NEPB researchers, Chinese officials and experts, and American 
administrators at the American Bureau for Medical Aid to China (ABMAC), a New York 
philanthropic organization that sought to establish a penicillin pilot plant in the United States 
for Chinese researchers, reveal the extent of the perceived and real difficulties in producing 
penicillin on a mass scale in China. I argue that discussions over an American pilot plant for 
Chinese penicillin manufacture, in which Americans sought to transfer technologies that the 
NEPB was already developing, did not only reflect the challenges that the calamitous 
environment of everyday wartime China posed for medical research. The negotiations also 
reflected the way in which ABMAC presented the difficulties of everyday life in wartime 
China as incompatible with, rather than simply inhospitable to, medical science. Such 
assumptions help explain why efforts to set up a pilot plant in the United States failed, even as 
efforts in China ultimately succeeded. After a discussion of early research into penicillin in 
China’s wartime hinterland, the paper considers the proposal by ABMAC to establish a pilot 
plant and discussions of the technical difficulties of establishing such a plant and transferring 
it to China. I then discuss the successful development of small amounts of therapeutic 
penicillin by the NEPB in 1944 and the impact of this event on the ultimate decision to 
redirect support for the pilot project to the NEPB at the end of the war. 
These materials, many of which are drawn from the ABMAC archives, recover an 
important narrative in the history of pharmaceuticals and chemotherapy in twentieth-century 
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China. The introduction of penicillin rarely features as an important event in the long sweep 
of Chinese medical historiography.9 Although there is a rich tradition in the history of 
pharmacy in China, the bulk of this scholarship has investigated traditional Chinese drugs. 
Aside from the work of the business historian Sherman Cochran, it has generally not focused 
on the history of foreign pharmaceutical enterprises or Western pharmaceuticals like sulfa 
drugs or other antibiotics. Miriam Gross and Xiaoping Fang have both discussed the 
significance of Western drugs for rural medicine and public health in the PRC.10 The pre-
1949 history of antibiotics in China can therefore provide valuable insights into their later use 
in China. Indeed, Wang Gaopeng argues that mass media played a crucial role in the 
acceptance and eventual veneration of penicillin in China as a miracle drug and that 
discourses of penicillin became a site for broader assertions of power by both the Nationalist 
and Communist Parties. And Frank Dikötter, Lars Laamann, and Zhou Xun have observed 
that the advent of penicillin and other antibiotics provided a viable alternative to some of the 
medicinal functions of opium, changing the landscape of therapeutic possibility in China.11 
This history also underscores the importance of the Second Sino-Japanese War as a 
catalyst for medical research in China. The history of wartime science and medicine in China 
has seen increasing attention from scholars like John Watt, Wayne Soon, and Nicole Barnes.12 
Yet the role of wartime work in antibiotic and pharmaceutical development has yet to be 
explored in full, especially given claims that Tang Feifan and his colleagues at the NEPB laid 
the foundations for the rise of the Western pharmaceutical industry in China. As Robert Bud 
writes, “Their expertise was crucial to the subsequent building of a global industry.”13 Bud 
                                                
9 For instance, it does not appear in a timeline of significant events in medical history in Zhen Zhiya, Zhongguo 
yixue shi, 560-571. 
10 Cochran, Chinese Medicine Men; Fang, Barefoot Doctors and Western Medicine; Gross, Farewell to the God 
of Plague. 
11 Wang Gaopeng, “Qingmeisu zai jindai Zhongguo,” 1; Dikötter, Laamann, and Zhou, Narcotic Culture, 205, 
208. 
12 Watt, Saving Lives; Soon, “Coming from Afar”; Barnes, Intimate Communities. 
13 Bud, Penicillin, 76. 
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gives the fullest Anglophone account of Chinese production of penicillin in his recent history 
of the drug, noting the surprising success of NEPB efforts in highly unfavorable conditions.14 
Xu Dingding and Niu Yahua have also written thorough accounts of Chinese penicillin 
production that stress the significance of the NEPB’s work in the wartime interior.15 These 
accounts enrich others that emphasize the rapid expansion of penicillin production after the 
1949 establishment of the People’s Republic of China, again suggesting the value of 
considering the role of war with Japan in this history.16  
The narrative of Chinese penicillin production also contributes to global histories of 
antibiotic development and use. Most histories of penicillin focus on the well-known story of 
Alexander Fleming’s 1928 discovery and Howard Florey’s development of the compound as 
an effective antibiotic agent, typically thought of as a key step in contributing to a golden age 
of biomedicine in the mid-twentieth century. Recent scholarship has challenged this belief. In 
the most comprehensive recent history, Robert Bud argues that the medical triumphs, and 
triumphalism, resulting from penicillin should be understood alongside darker narratives of 
irresponsible misuse and overprescription.17 Peter Neushul suggests that the crisis of the 
World War II was crucial to facilitating the development of penicillin as a modern wonder 
drug because of the alliance it brought between state and industry in North America.18 Nicolas 
Rasmussen notes, however, that much of the industrially and philanthropically funded 
apparatus commonly thought to characterize “big biology” was already in place in the United 
States by the outbreak of war there in 1941; it was the novelty of federal patronage that 
transformed American biomedical research during this time.19 
                                                
14 Bud, Penicillin, 81. 
15 Xu Dingding, “Kangri zhanzheng shiqi”; Niu Yahua, “20 shiji 40 niandai.” 
16 For an example, see Zhongguo yiyao baokan xiehui and Zhongguo yiyao gongye yanjiu kaifa cujin hui, Xin 
zhongguo yaopin jianguan yu fazhan jingdian huicui, 139-141. 
17 Bud, Penicillin, 2. 
18 Neushul, “Fighting Research.” 
19 Rasmussen, “Of ‘Small Men,’ Big Science and Bigger Business,” 116-117, 121-125. 
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Outside English and American ambits, Bud notes that news of penicillin spread 
rapidly around the world, even in the constrained and secretive environment of war. Moreover, 
despite its theoretical and technical novelty, penicillin manufacture quickly became a priority 
for national governments across Europe and in China, Japan, and (postindependence) India.20 
The development and circulation of penicillin in Japan is particularly noteworthy. Julia 
Yongue describes the mass production of penicillin in Japan as an unusual case of technology 
transfer from the United States in which scientists and government officials, rather than 
pharmaceutical firms, played central roles, and in which the absence of patenting until the end 
of the American Occupation facilitated novel and often productive relationships between 
science, state, and industry.21 However, Victoria Lee argues that rather than technology 
transfer, we should understand the Japanese case as one of “domestication” in which 
indigenous knowledge from the wartime and prewar periods of Japanese empire, drawing 
upon established concepts of microbes as agents of transformation that produced abundance 
from scarcity, contributed crucially to biomedical development.22 Scholarship on Japan is 
instructive for the case of China; as Lee’s piece suggests, the uneasy exchanges between 
Chinese and American actors over the penicillin pilot plant proposed by ABMAC complicate 
notions of straightforward technology transfer to the Republic of China that American 
consultants sought to execute. 
 
Kunming: The Context of Wartime Medical Research and Drug Production 
Although southwest China had heretofore been a borderland at the fringes of modern 
public health and medical intervention, during the war the region became the epicenter of 
health administration for unoccupied China. After the Japanese invasion and occupation of 
eastern China forced the Republic of China’s central administration to move from Nanjing to 
                                                
20 Bud, Penicillin, 75-82. 
21 Yongue, “Introduction of American Mass Production Technology,” 213. 
22 Lee, “Microbial Transformations,” 441-442. 
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Chongqing, a number of government officials, professionals, and intellectuals migrated with 
it to China’s western interior in 1938. Among the central government organizations that 
moved were the National Health Administration, which established its provisional 
headquarters in Geleshan outside Chongqing, and the NEPB, which reestablished its 
laboratories in Kunming, the capital of Yunnan Province. 
The NEPB was the official manufacturer of vaccines, sera, and other “biological 
products” for the Republic of China. Founded in 1919 in response to a local outbreak of the 
plague in north China, its work quickly grew over the next years to include biomedical 
research on communicable diseases, epidemiological data collection, and the development of 
vaccination campaigns.23 During the 1920s and 1930s, the NEPB expanded its remit and 
capacities, adding a new branch and moving its headquarters to Nanjing in 1935. By this 
point, it had become a central entity in efforts to control and eradicate communicable diseases 
in China, and its offices manufactured over 40 different types of sera, vaccines, and antitoxins 
against human and animal diseases.24 When Tang Feifan assumed directorship of the bureau 
in 1938, he was in flight from Shanghai, where he had served as head of the Department of 
Bacteriology at the Henry Lester Institute of Medical Research and taught at the medical 
college at the prestigious National Central University (Guoli zhongyang daxue).25  
Although the NEPB had left behind its relatively grand, well-equipped offices in 
Beijing, Nanjing, and Shanghai—the original Beijing bureau of the branch had been housed at 
the Temple of Heaven—in Kunming it continued its work of manufacturing biomedical 
materials and retained a number of highly trained specialists in its employ. Between 1937 and 
1945, the NEPB produced millions of doses of vaccines against smallpox, cholera, and 
                                                
23 Yip, Health and National Reconstruction, 16.  
24 Chen, “Public Health in National Reconstruction,” 60-68. 
25 Cheng, Ming, and Gao, “Recollection;” Wu Anran and Xie Xiaowen, “In Memory of Professor Tang Fei-fan,” 
512. Although National Central University was based in Nanjing, its medical school was sited in Shanghai 
during the 1930s. 
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typhoid fever.26 The Kunming headquarters oversaw branch laboratories and offices at 
Guiyang and Lanzhou. Because the capital of Yunnan was a site of major American and 
Allied activity as the eastern terminus of the Burma Road, it was relatively well connected to 
communications networks. The staff of the NEPB was therefore well placed to receive the 
news of penicillin’s successful therapeutic development in the West. 
Every week, Tang Feifan ran what modern biomedical laboratories call a journal club: 
a meeting to discuss new publications in foreign scholarly journals. In the autumn of 1941, 
Wei Xi, a bacteriologist and senior specialist at the NEPB, reported to this club on an August 
Lancet article by scientists at Oxford including Howard Florey and Ernst Chain on the 
extraction, purification, and assay of penicillin as an antibiotic drug.27 The NEPB staff was 
inspired by the news of penicillin’s successful therapeutic use and especially the suggestion 
by the Lancet paper’s authors that it would help the Allied war effort.28 The Chinese 
researchers henceforth begin using their spare time to investigate the southwestern 
environment—considering everything from old shoes and clothing to antique coins and local 
melons29—to see if molds suitable for cultivating Penicillum notatum could be identified. The 
keen interest of NEPB staffers was not at all an isolated phenomenon, but rather part of what 
Wang Gaopeng describes as a “fanatical worship” (kuangre chongbai) of penicillin reflected 
by enthusiastic discussion in Chinese medical discourses and mass media in 1944 and 1945. 
Prominent intellectuals like Tao Xingzhi discussed penicillin as a political metaphor for good 
governance in calls for reform of the Nationalist state. It also became a fashionable term in 
broader popular culture, and the use of penicillin as a miraculous new panacea became a plot 
                                                
26 See also Brazelton, Mass Vaccination. 
27 Xu Dingding, “Experimental Production of Penicillin,” 323; Bud, Penicillin, 79-81; Xu Dingding, “Kangri 
zhanzheng shiqi,” 349; Abraham et al., “Further Observations on Penicillin.” 
28 Xu Dingding, “Kangri zhanzheng shiqi,” 349; for a firsthand account, see Tang Feifan, “Wu guo zi zhi 
qingmeisu.” 
29 Tang Feifan, “Wu guo zi zhi qingmeisu,” as quoted in Xu Dingding, “Kangri zhanzheng shiqi,” 350. 
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point in literary and cultural productions ranging from farces to short stories.30  
Amid this public enthusiasm, NEPB’s search for a suitable mold took years, until the 
spring of 1944. During this time, Tang Feifan and his colleague Huang Youwei traveled to 
India with support from the Rockefeller Foundation to survey public health organizations 
there; they returned to China with 10 strains of penicillin that had been isolated in England 
and America. Furthermore, a Chinese microbiologist returning from the University of 
Wisconsin, Fan Qingsheng, brought an additional three strains. The NEPB also obtained 
strains of penicillin from the United States Northern Regional Research Laboratory in Peoria, 
Illinois, where researchers had developed “deep” fermentation methods to culture penicillin 
within, rather than atop the surface of, a liquid medium. Yet both strains from this source 
performed poorly in attempts to culture penicillin; Tang and his colleagues suspected one of 
“dissociation with resultant loss of potency,” perhaps as a result of the long journey from 
Peoria to Kunming.31 Despite this surfeit of strains with which to experiment, it was still not 
easy to identify molds with antibiotic properties—but eventually one was found.32 
Contemporary narratives do not agree on the source of the mold that became the basis for 
penicillin production in China. Xu suggests that Lu Jinhan isolated it from meat broth, while 
Niu claims a mold on a broom yielded 11 strains with antibacterial properties.33 But once the 
NEPB had identified and isolated strains of mold that exhibited antibacterial properties, 
whatever the source, its staff sought means of cultivating and purifying the strains. 
Meanwhile, the first industrially produced penicillin reached Chinese hospital beds. 
After the Lend-Lease Act permitted the transfer of 465 ampoules of penicillin from the 
United States to China, China’s National Health Administration established a Central 
                                                
30 Wang Gaopeng, “Qingmeisu zai jindai Zhongguo,” 19, 39-42. For an overview of the explosion of Chinese 
medical literature on penicillin at this time, see Zhang Changshao, Qingmeisu yu lianmeisu. 
31 Chu, Wong, Fan, and Tang, “Experimental Production of Penicillin,” 91. 
32 Chu, Wong, Fan, and Tang, “Experimental Production of Penicillin,” 90. The local molds were gathered over 
fourteen months from May 1944 to July 1945 and included such sources as orange peels, shoes, and cheese. 
33 Xu Dingding, “Kangri zhanzheng shiqi,” 350; Niu Yahua, “20 shiji 40 niandai,” 185. 
 11 
Penicillin Control Committee in the wartime capital of Chongqing to provide guidance for the 
drug’s administration, establish cold storage facilities, and distribute penicillin to designated 
sites.34 The first clinical uses of the drug were extremely positive. A report of 33 patients 
treated with penicillin in the Chongqing Central Hospital between August and November 
suggested that 19 men and women of a wide range of ages showed partial or clear 
improvement. A report of the committee summarized, “All the cases of pneumonia, chronic 
osteomyelitis, and acute infections due to staphylococci have responded remarkably well to 
treatment.” The group planned to expand distribution to other cities in the unoccupied interior 
and estimated that China would need six hundred million Oxford units of the drug for the year 
1945 (the initial shipment of 465 ampoules had contained 46.5 million units).35 Given just a 
taste of the abilities of penicillin, Chinese health administrators hungered for a fuller supply. 
 
New York: ABMAC Proposes a Penicillin Plant 
Throughout the fateful summer of 1944, these events had transpired at the edges of the 
Western world, through Sino-Indian relationships and local research efforts. Yet another 
group, ABMAC, was seeking the same result—penicillin production on a large scale in 
China—through radically different means. As John Watt has shown, ABMAC played a 
crucial role in the provision of wartime medical services to the Nationalist regime.36 Founded 
in October 1937 by overseas Chinese and Americans in New York, the organization funded 
many projects across wartime Nationalist territory. Over the course of the war, it sent a total 
of $9.5 million to China, in a powerful projection of Chinese-American wealth and political 
                                                
34 Preliminary Report of the Central Penicillin Control Committee with Special Reference to the Activities of the 
Subcommittee for Civilians, January 25, 1945, p. 1, Archives of the American Bureau for Medical Aid to China, 
box 24. 
35 Preliminary Report of the Central Penicillin Control Committee with Special Reference to the Activities of the 
Subcommittee for Civilians, p. 2, and Table II, The Hospital Number, Age, Sex, Clinical Diagnosis, Laboratory 
Findings, Dosage and Therapeutic Effects of Penicillin of 33 Cases in the Chungking Central Hospital Covering 
from August to November 1944, January 25, 1945, Archives of the American Bureau for Medical Aid to China, 
box 24.  
36 Watt, Saving Lives.  
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power. A key Chinese health administrator heavily involved in ABMAC was Lin Kesheng 
(Robert Lim), the prominent—and polarizing—general who advocated and fundraised for 
Chinese military medicine.37 
Nicole Barnes notes that a widespread faith in the ability of modern Western scientific 
medicine to save lives suffused the spirit of donations to Chinese medical aid programs 
during the war.38 The activities of ABMAC thoroughly manifested such a spirit, as it worked 
with the National Health Administration and the Chinese Red Cross to allocate funds for the 
purchase of medical supplies and equipment. ABMAC also sponsored projects to purchase 
and send textbooks, journals, and anatomical and pathological microscope slides from the 
United States to medical schools in the wartime southwest, as well as postgraduate fellowship 
training for Chinese candidates at American medical schools. In 1943, the organization also 
established the first Chinese blood bank in Kunming. Wayne Soon has drawn attention to the 
significance of ABMAC in funding and establishing this project and the ways in which 
cultural understandings, nationalism, altruism, and economic crisis all contributed to the 
social meanings of blood that shaped the bank’s activities.39 
It was after the blood bank’s establishment, in the spring of 1944, that ABMAC 
staffers first contemplated the development of a penicillin production plant in China. The 
notes of a meeting in New York on the afternoon of March 6, 1944, chaired by Liu Ruiheng 
(J. Heng Liu), previously vice-minister of health and now medical director of the US-based 
China Defence Supplies Commission,40 revealed ambitious desires. Unable to purchase 
penicillin directly for distribution in China, the group decided to focus on making it possible 
for Chinese microbiologists to produce the drug themselves. They would accomplish this by 
first establishing a small pilot plant in New York jointly with Indusco, the American 
                                                
37 Watt, Saving Lives, 123-158; Soon, “Coming from Afar.” 
38 Barnes, Intimate Communities, 128. 
39 Soon, “Blood, Soy Milk, and Vitality,” 427. 
40 “Death of Dr. Liu,” 2.  
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Committee in Aid of Chinese Industrial Cooperatives.41 The goal was explicit technology 
transfer: to develop methods of producing crude and refined penicillin that “would, as far as 
possible, use only materials and equipment available in China.” The minutes of the meeting 
further stipulated, “The method decided upon might not be the most efficient method for 
America, but it would be the best for China because of availability of materials and 
equipment.”42 Norman Applezweig, a chemist and Indusco consultant involved in the project, 
reinforced visions of the project as a simple problem of technology transfer: “How can we 
transpose the highly mechanized American industrial practice into simple and more primitive 
conditions under which this industry must function in China?”43 
Early plans for the pilot plant were unclear in most details, except one: a young Johns 
Hopkins-trained bacteriologist from China named Tong Cun would be trained in methods of 
penicillin production in order to lead the plant’s transfer to China. Tong had been born into a 
Manchu family of officials who had served in the education administration of the Qing 
Dynasty. After receiving degrees from Yenching University and Peking Union Medical 
College, Tong had traveled to the United States, where in 1941, he received a doctorate of 
science from Johns Hopkins and became an instructor in bacteriology.44 The plan that 
ABMAC staffers developed in March 1944 was for Tong to “experiment on methods of 
producing penicillin until one was found which would be practicable in China and then ship 
the pilot plant to China as soon as possible” to supply the Chinese army with the drug.45 Tong 
himself would also return to China to supervise the operation of the plant, the training of 
                                                
41 Report on the Meeting of the ABMAC Penicillin for China Committee, September 22, 1944, Archives of the 
American Bureau for Medical Aid to China, box 24. The industrial cooperative movement in China began in 
1938 as the work of H.H. Kung, minister of finance, and the New Zealander Rewi Alley. Pruitt, “Six Years of 
Indusco,” 48. 
42 Minutes of Conference on the Production of Penicillin, March 6, 1944, Archives of the American Bureau for 
Medical Aid to China, box 24. 
43 Speech Given at ABMAC Annual Board of Directors Meeting by Norman Appelzweig, May 16, 1944, p.1, 
Archives of the American Bureau for Medical Aid to China, box 24. 
44 Jin Xinghua, Gongheguo shaoshu minzu kexuejia chuan, 71-72. 
45 Report on the Meeting of the ABMAC Penicillin for China Committee, September 22, 1944, Archives of the 
American Bureau for Medical Aid to China, box 24. 
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personnel, and the establishment of new production laboratories in cities across unoccupied 
territory. ABMAC representatives originally planned to request funds from the Christian 
missionary organization United China Relief for this project.46 
  Plans for the mobile laboratory reflected American ideals of technology transfer as a 
medium for foreign diplomacy, as well as an opportunity to publicize (and possibly monetize) 
American scientific achievements. At the annual Board of Directors Meeting of ABMAC on 
May 16, Applezweig gave a speech to stakeholders unveiling the plans for the penicillin 
plant. He stressed the guidance ABMAC had received from government and commercial 
entities, stating somewhat hyperbolically that “the mere mention of the magic word China has 
opened to us the hearts and the minds of American research scientists and technical experts.” 
He suggested that the pilot plant was more than a means of getting drugs to China. “We are 
sending to China not only a method for producing penicillin to meet its dire health needs,” 
Applezweig proclaimed. “We believe we are sending to China a technique for research on and 
production of anti-biotic substances of which penicillin is only the first link in the chain.” He 
concluded: “In addition to its anti-biotic properties, penicillin will act as a strong cement to 
permanently bind the friendship which the Chinese and American people feel for each 
other.”47 The goal of political alliance was explicit; less so was the way in which 
Applezweig’s vision of the relationship assumed total Chinese dependency on American 
ingenuity and benevolence.  
 
New York: The Technical Challenges of Technology Transfer 
Despite the hyperbolic language employed by Applezweig and others, the American 
model of pharmaceutical production that was going to do so much for the Chinese people was 
                                                
46 Report on the Meeting of the ABMAC Penicillin for China Committee, September 22, 1944, Archives of the 
American Bureau for Medical Aid to China, box 24. 
47 Speech Given at ABMAC Annual Board of Directors Meeting by Norman Applezweig, May 16, 1944, pp. 1-
4, Archives of the American Bureau for Medical Aid to China, box 24. 
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not yet stable. The science and technology of penicillin manufacture was changing so much, 
and so quickly, that it was extremely unclear what a pilot plant would entail. In June 1944, a 
joint meeting of ABMAC and Indusco representatives concluded that “because of the rapidly 
changing picture in the production of penicillin…the Committee recommends that no definite 
commitments as to the rental of a laboratory or further purchase of supplies for the pilot plant 
be undertaken until a report has been made by the Penicillin for China Committee on the 
scientific aspects.”48 Another meeting later in the same month specified the technical 
problems anticipated for any large-scale penicillin plant in China, but failed to offer any 
productive solutions.  
Much depended upon the technique of production chosen. As a mold, penicillin was 
not produced through chemical synthesis, the typical model for industrial pharmaceutical 
production at the time, but rather through methods of fermentation that sped the growth of 
fungal cultures. The drug could be manufactured through one of two methods: the bottle, or 
the tank. In the former method, originally developed in Oxford, the penicillin mold grew on 
the surface of a liquid broth, contained in bottles laid on their side to provide the maximum 
surface area possible for replication of the mold. Research at Northern Regional Research 
Laboratory in Peoria, Illinois found that deep-tank fermentation methods, in which penicillin 
was introduced with oxygen to large vats containing a nutrient broth, greatly increased 
production rates.  
Which method should be used in China: the bottle or the vat? The concern for 
ABMAC and the Indusco staff was that in China, neither of these methods seemed viable. 
The bottle method seemed slow and outdated, but the tank method required too much 
specialized equipment and complex upkeep. Both methods used chemicals that were readily 
available in the United States, but not in China: specifically lactose and corn steep liquor. 
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Lactose was the major carbon source for penicillin production but was not available in China 
and would need to be replaced by more readily available starches that had been dextrinized, or 
broken down into constituent sugars.49 Corn steep liquor, a by-product of corn wet milling 
and key additive to penicillin growth cultures, was another issue. “The discovery that corn 
steep liquor added to culture medium increases penicillin yield by many times forms the 
milestone upon which is built the penicillin production industry in its present scale,” 
explained Tang Feifan and colleagues at the NEPB in 1945. “Corn steep liquor is a product of 
the starch fermentation industry and is not available as such in China.” What had made sense 
for a laboratory in the corn country of Peoria, Illinois, was not going to work in Kunming.50  
All of these technical problems only pertained to the first phase of penicillin 
development. It was one thing to stimulate the growth of penicillin mold in vats and bottles, 
but quite another problem to extract a usable drug from the solution. Again, methods for 
extracting penicillin commonly used in the United States relied on chemical agents not 
available in China, notably organic solvents and activated charcoal. “The extracting reagents, 
either organic solvent or charcoal, should be solved before we talk about production,” Tong 
told ABMAC. He proposed starting with the bottle method of production, noting that “we 
could reach quite a sizeable production in China. If we do not have the bottles, we could use 
crude porcelain vessels as well.”51 
Tong’s comment nodded to other anticipated problems and fundamental worries on 
the part of the American participants, which had to do with the basic conditions of wartime 
China. The question of maintaining sterile conditions—a specter that haunted every biological 
and chemical laboratory in wartime China—was a pressing one, as was the ability of any 
given institution to maintain consistent refrigeration of strains. The more general dearth of 
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experts in Western medicine was a constant worry. The philanthropist and chemist Donald 
Othmer said at one point, “If you start in China with people who have not been trained here 
you are back to the 1929 method.”52 However, as Tong Cun pointed out in one New York 
meeting, “It will be difficult in China to get well trained personnel on penicillin. We do not 
have people here either.”53  
The anticipation of problems related to the adaptation of penicillin production thus 
revealed a perceived gap between the United States and China, not only in terms of specific 
technical questions like the scarcity of activated charcoal in China, but also in terms of how 
the wartime environment shaped the possibilities of microbiology. The debate was 
fundamentally over the standard operating conditions of medical research in China, and the 
ways in which Americans assumed such conditions to be inadequate and antithetical to the 
mass production of penicillin.  
Given these technical concerns, there was fundamental disagreement as to whether 
ABMAC’s plan was the best way forward. “I have maintained from the beginning that it is 
very important to send certain special equipment and one or two experts to China as soon as 
possible,” wrote Liu Ruiheng in a June 1944 memo. “There are advantages to setting up a 
complete test plant in New York and then to ship the whole outfit to China, but this will take 
too much time and there will be difficulties such as those facing the Blood Bank today.” He 
recommended instead that Tang Feifan come to the United States from Kunming to study 
penicillin manufacture and purchase equipment that could make the NEPB a penicillin 
production center.54 Lin Kesheng also advocated for the redirection to the NEPB of the 
funding and supplies ABMAC had allocated for its own penicillin plant. He wrote, “If…we 
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might get enough equipment, we might use the Epidemic Prevention Bureau and set up a real 
plant.”55  
Another setback emerged from efforts on the part of Indusco, the American group 
supporting Chinese industrial cooperatives, to seek the sponsorship of commercial partners 
and secure for Tong Cun research experience in an industrial laboratory. The question of 
industrial involvement in penicillin production was a loaded one. In the United States, 
pharmaceutical companies that had contracted with the federal government to produce 
penicillin during the war nevertheless anticipated that the drug as a proprietary product would 
be phenomenally lucrative after the end of conflict. “After the war penicillin will be a purely 
commercial product and the tricks of the trade will be kept secret,” noted Donald Van Slyke, a 
preeminent chemist at the Rockefeller Institute for Medical Research and a cofounder of 
ABMAC, in a June 1944 meeting.56 Although Indusco sought aid from a pharmaceutical 
company to establish a pilot plant in the United States, with the incentive that the firm would 
have first rights to establish facilities in China after the war ended, its efforts were 
unsuccessful.57 A letter from Helen Stevens, the executive director of ABMAC, to K.K. Chen, 
director of pharmacological research at Eli Lilly’s research laboratories, shed some light on 
this question. Stevens summarized a conversation they had had several days previously, in 
which Chen suggested that “no commercial plant would be willing to let Dr. Tung [Tong] in 
on their trade secrets; therefore, if Dr. Tung is to obtain practical experience it will have to be 
in a pilot plant.”58  
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By midsummer, ABMAC members deemed it necessary to consult higher authorities. 
On July 13, 1944, Donald Van Slyke, Lin Kesheng, and Liu Ruiheng, all representing 
ABMAC, met with Frederick J. Stock, of the Office of Production Management in the United 
States War Production Board, and Dr. Chester Keefer, chairman of the National Research 
Council’s Committee on Chemotherapy (responsible for rationing penicillin supplies for 
civilian use) in Washington, DC. The representatives from ABMAC asked the American 
officials how practical it would be to establish a plant under the direction of Tong Cun to 
produce penicillin in China. The response was encouraging; Stock and Keefer suggested that 
the project establish a small laboratory that could be set up within three months and produce 
one hundred million Oxford units of penicillin per month, using the bottle method of 
production.59 They recommended that the site should be one, in the words of Lin Kesheng, 
“where we could work day and night, and where we could have complete freedom.” A few 
days later, on the evening of July 19, ABMAC held its own meeting at its offices on 
Broadway. Two bacteriologists, Robert Coghill (who had directed penicillin research at the 
North Regional Research Laboratory in Peoria) and his colleague George Ward, had been 
specially invited to discuss the technical problems of a pilot plant. 
In the course of the discussion, a consistent theme that emerged was the question of 
what exactly would be the most useful means of getting penicillin to China. Embedded in the 
conversation were, again, assumptions about what was “normal” in China versus America. 
The discussion seems to have been precipitated by the news that a donor had given one 
million dollars to United China Relief for the purchase of drugs to supplement what the 
Chinese government could buy through the Lend-Lease program. Van Slyke observed, “It 
appears to be the consensus of opinion that it is desirable…to get as much penicillin to China 
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as possible as soon as possible.”60 The meeting notes recorded the purpose of the penicillin 
purchases that the Chinese government was making through this agreement from the War 
Production Board: “The supply of penicillin would be just sufficient to give experience to 
doctors in China but would not take care of sufficient number of cases to have any great effect 
on the army casualties.”61 The message was clear: this pilot project was not going to affect the 
everyday lives of soldiers or civilians in wartime China. Left unspoken, however, was the 
possibility that it might shape the course of the war to come between the Nationalist Party and 
the Communist Party. 
Not everyone agreed with this course of action. Liu Ruiheng protested the small 
amounts of penicillin being sent to China, saying, “Treating 50 cases a month does not mean 
anything at all.” Van Slyke responded, “The denying of penicillin to China, just because she 
does not know how to use it is just like telling your daughter to stay away from the water until 
she knows how to swim.” Coghill responded, “[Frederick] Stock is extremely sympathetic. If 
you can get by political interference amount available will increase very fast, as I know 
production will increase rapidly.” And George Ward pointed out to the Chinese participants 
that “learning bottle method will never teach you how to run a tank plant.” There was also 
further discussion of the technical nuts and bolts: Did China have sufficiently reliable 
infrastructures of electric power? How could activated charcoal be produced there? Could 
wood distillate provide sufficient materials for amyl acetate, and could soybean extract 
replace steep liquor? When the meeting adjourned at 10:30 pm, these questions remained 
largely theoretical, but they had the cumulative effect of suggesting that the problems of 
transferring penicillin production technology to China were prohibitively manifold.62 
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Kunming: The Cultivation of Penicillin at the NEPB 
In the summer of 1944, senior specialists at the NEPB had identified strains of mold 
that demonstrated antibacterial properties, but struggled to cultivate them, much less extract a 
viable pharmaceutical compound. The team dedicated to this work was led by Tang Feifan 
but included senior specialists Huang Youwei and Zhu Jiming, the latter of whom worked 
especially intensively on the project. Fan Qingsheng, an American-trained bacteriologist at 
the blood bank ABMAC had founded in Kunming, quickly became involved as well. At the 
same time, Tang was corresponding frequently with Tong Cun in the United States.63 
As ABMAC discussions had indicated, a major problem for the cultivation of 
penicillin in China was the unavailibility of corn steep liquor, the crucial additive for culture 
mediums. The NEPB staffers who faced this problem had to come up with practical 
alternatives. They used a combination of cane sugar, available locally, and a liquor they 
distilled from corn specially for penicillin production.64 After incubation of the flasks 
containing the growth preparation, the researchers extracted the penicillin using methods that 
Tong Cun had discussed with ABMAC. The fundamental problem had been the limited 
availability of organic solvents and activated charcoal. Tang’s team used amyl acetate to 
extract penicillin into aquaeous solution, employing a filter of sand and silk layers to separate 
the solvents. The NEPB then added charcoal obtained from a local sugar refinery supplier to 
the solution; further filtration, drying, and other chemical methods produced a concentrated 
solution that could be used therapeutically.65 
On September 5, the NEPB produced 5 ampoules of penicillin, each containing five 
thousand Oxford units. Two were sent to the wartime capital at Chongqing and one each went 
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to Norman Heatley at Oxford and to the University of Wisconsin, Madison; the NEPB kept 
the final bottle for itself.66 Assays at Oxford and the University of Wisconsin confirmed that 
the Chinese production contained 177 Oxford units of penicillin per milligram.67 The second 
batch of penicillin that the NEPB produced was sent first to the local Huidian Hospital 
(Huidian yiyuan), where physician Yao Hanping used it to treat a selection of patients and 
saw remarkable improvement in otherwise hopeless cases, and later to the Kunhua Hospital 
(Kunhua yiyuan).68 
The article that Tang Feifan and his colleagues published in 1945 announcing their 
achievement was the cover story of that month’s Chinese Medical Journal. In the piece, they 
described the challenges they had faced in the course of experimental production, attributing 
most of them to the poor facilities and lack of available equipment in the wartime interior. For 
instance, it was easier to send assays abroad than to try to perform them in China. “It is often 
difficult to obtain glass or porcelain cylinders of well beveled end to permit a satisfactory 
seal” in attempting the standard Oxford method, explained the 1945 paper’s authors, who then 
went on to describe a method they had developed to perform the assay using a cork borer to 
place holes on the seeded agar.69 The team completed clinical trials, but in its initial report 
cautioned that “the dosages are entirely arbitrary and in general the total amount given is far 
too small to permit any clinical judgement”; instead, their trials simply proved that the 
penicillin the NEPB had developed could be used therapeutically.70 
ABMAC heard the news more or less as it happened because Fan Qingsheng, the 
bacteriologist for the blood bank that ABMAC ran in Kunming, quickly became involved in 
the penicillin project. “Two weeks after my arrival at Kunming, I moved down to the West 
Hill and started work on culture of the mold and the extraction of penicillin with Dr. Tang and 
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his staff,” explained Fan in a report that he sent to ABMAC on September 4. The report 
characterized the work as a “joint project” of the NEPB and the blood bank and described its 
equipment, experimental results, and current production levels. A brief summary of the 
patients cured with penicillin in the first experimental trials gives a sense of the kinds of 
medical problems that merited treatment, many of which had nothing to do with war at all: 
“large carbuncle on back,” “staphylococcus infected dog-bite wound,” “fistula following 
empyema as complication of pneumonia.”71  
The news that the NEPB had managed to produce viable penicillin complicated the 
ambitions of ABMAC. At 5:30 pm on September 22, 1944, the Penicillin for China 
Committee met at the ABMAC offices on Broadway in New York. The news was 
disheartening. Negotiations between Indusco and a commercial partner had failed, and recent 
experiences of the blood bank in Kunming had suggested that “it is not at all practical to send 
a trained team and American made equipment to China.” The fact that Tang Feifan had 
already begun producing small quantities of penicillin domestically made it all the more 
absurd to contemplate such a project.72 The success of domestic production in wartime 
circumstances made it rather strange that such a complex, expensive project of technology 
transfer from America should founder. Even as the committee was deciding on the 
impossibility of the transfer, it was happening. Wartime conditions of scarcity and 
substitution, which had presented fearsome obstacles to American technology transfer, had 
nonetheless provided the means for Chinese manufacture of the drug. 
 
From New York to Kunming and Kunming to Beijing: Repatriations amid Civil War  
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Given the developments in Kunming, it was now very unclear how the transfer of a 
separate penicillin plant from the United States to China, while useful, would effect radical 
transformation of the kind Applezweig and others had originally envisioned. At the 
September 1944 meeting, committee members concluded that “a pilot plant is no longer 
feasible” and that it should “support Dr. F.F. Tang, who is producing penicillin in China, by 
buying equipment for him and sending Dr. Tsun Tung [Tong Cun] back to China as soon as 
possible to help in the production of penicillin there.” ABMAC would also purchase as much 
penicillin as possible to send to China.73 On January 13, 1947, Tang acknowledged receipt, on 
behalf of the NEPB, of $18,745,000 (in Chinese currency) from ABMAC in support of the 
penicillin plant.74  
On October 1, 1944, Tong—who was being repatriated despite stating 10 days 
previously that he felt he lacked the training to successfully return and launch penicillin 
production in his native country—wrote an impassioned letter to ABMAC’s executive 
director, Helen Stevens. It suggested Tong’s fear that Chinese colleagues would think poorly 
of him for not doing more to effect penicillin production in China: “I do mind,” he wrote, 
“that people in China will blame me if I cannot do anything more than they can do now.” He 
emphasized his dedication to ABMAC and stressed the need for Chinese researchers to travel 
to the United States to learn more about the drug’s manufacture there. “I am afraid that while 
we have painstakingly paved the way for the making of penicillin for China,” he wrote darkly, 
“we might not have the opportunity to use it to any extent.”75  
By the end of the month, Tong’s spirits appeared to have lifted. In a second letter to 
Stevens, he sent a plan of action to prepare for his return to China. Before sailing across the 
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Pacific, he would spend two weeks at Penn State to study the means of extracting penicillin 
from culture, then a month at the Peoria Laboratory to learn more about the tank method of 
penicillin cultivation. Finally, he would spend two weeks at the commercial laboratories of 
Eli Lilly and Squibb, having apparently found a way to access those industrial laboratories 
after all.76 “I expect that in the next one or two years every bacteriologist in China will 
become keenly interested in penicillin and a corresponding number of chemists will become 
familiar with the making of penicillin,” he wrote, before going on to request some equipment 
to take with him back to China. In addition to glassware and lactose, Tong asked for $2,000 to 
be set aside for the manufacture of “miniature tanks and accessories,” which he apparently 
intended to use as teaching tools.77 On July 7, 1945, Tong made a further plea for material 
and financial support for penicillin production even though the war was drawing to a close, 
based on the project’s lasting significance. “We in China shall stand by this work, war or 
peace,” he asserted.78  
The end of World War II did not augur peace for China, soon beset by civil war 
between the Communist Party and the Nationalist Party. Nevertheless, shortly after the 
Japanese surrender, the National Health Administration and other state medical institutions 
made triumphant returns to eastern China’s formerly occupied urban centres. The NEPB, too, 
reestablished its offices in Beijing and Nanjing. Penicillin production, supported by ABMAC, 
was by now a fundamental part of its work, and Tang ensured the establishment of an 
antibiotic research laboratory within its Beijing headquarters as they were rebuilt after the 
war; Tong Cun assumed leadership of this office upon his return from the United States.79 
Tang reported in December 1948 that monthly yields since August of that year had doubled 
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using chemical methods and then stood at about 1,500 bottles, each containing two hundred 
thousand units of penicillin. From August 1948, the NEPB had doubled this figure using 
chemical methods. The NEPB had switched from a bottle method to the vat, using four 30-
gallon cultivation tanks; Tang hoped to acquire two 300-gallon tanks in order to expand 
production more rapidly, but noted that efforts to have this equipment made locally had 
failed.80  
Tang wrote to ABMAC member Frank Meleney in March 1946, shortly after the 
NEPB had returned to its facilities in Beijing. “The National Government has given us a 
special grant to build a penicillin laboratory to house the equipment which you have so kindly 
bought for us,” he explained, and asked Meleney to purchase some additional equipment, 
including a centrifuge and electronic microscope. He hinted that the latter might not be solely 
for the purpose of producing penicillin, saying, “I have been interested in the study of 
filterable viruses for many years and I would like to have an Electronic microscope for further 
work on the subject.”81 This request suggested that Tang was trying to make the fullest use of 
a resource that he knew might not last much longer—after all, the end of war with Japan had 
removed the primary justification for the existence of ABMAC, even if civil war was only 
just beginning (again). 
ABMAC did not close its operations, but did refocus them on a program offering 
fellowships to faculty at national medical schools in China. Meanwhile, other organizations 
emerged to facilitate penicillin production. The most significant of these was a postwar 
initiative by the United Nations Relief and Rehabilitation Agency (UNRRA) to provide 
expertise and equipment in the manufacture of penicillin to war-torn nations. The project 
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focused on Eastern Europe, but indirectly extended as far as China.82 In China, the Chinese 
National Relief and Rehabilitation Administration (Xingzheng yuan shanhou jiuji shu) was 
established to distribute aid from UNRRA. In 1945, its Jiangxi Province branch received a 
small batch of penicillin that was sufficient to treat 79 patients, many of whom recovered 
fully.  
Like others with access to the drug, the physician overseeing experimental treatment 
in Jiangxi presented these initial cases as materials of interest and significance in medical 
literature.83 Although Tang Feifan fretted over the quantity of penicillin he could produce at 
the NEPB in Beijing, researchers across China were excited to make use of this new 
therapeutic measure. They began publishing articles about their research using small amounts 
of penicillin in clinical contexts. Researchers focused on the ways in which penicillin might 
successfully treat pathologies especially common in China. They tried to use penicillin to 
treat lung abscesses, complications of kala-azar (the parasitic disease leishmaniasis), blood 
clots in sinus cavities, and Chinese louse-borne relapsing fever.84 They wrote of their 
experiences injecting penicillin directly into the spinal column.85 One physician went so far as 
to invent a machine for aerosolized penicillin distribution, suggesting in the Chinese Medical 
Journal that penicillin in such a form could serve as an effective means of treating lobar 
pneumonia and other pulmonary diseases. The author stressed that the apparatus could be 
made easily from materials at hand in most places in China, a significant advantage given that 
foreign nebulizers were unavailable “on account of the present political situation.”86  
Yet as the final quote indicates, this excitement took place at a time of great change. 
Tang ended his December 1948 report to ABMAC with an ominous meditation on the future. 
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Although the NEPB was functioning as usual in terms of its production, it had also become 
the site of a military hospital and was functionally besieged by several different groups of 
soldiers who “wanted to use the laboratory buildings for their purposes.”87 In a postwar 
environment of rapid social and political change, staffers left the NEPB, and China, in a 
steady stream. In September, Tong Cun took up a position supervising penicillin production 
in Shanghai,88 and Ma Yucheng flew to Toronto to take up a WHO fellowship for advanced 
training in antibiotics. Tang noted that two workers in the assay department “left the 
laboratory in September and October—both to get married.”89 Although the turmoil of civil 
war was rapidly engulfing Beijing, the Ministry of Health instructed the NEPB not to move 
the penicillin plant, or any of its other offices, out of the city.90 Tang explained, “As there is 
safety and peace nowhere even had we the finances for any major removal, we have decided 
finally to let this laboratory—together with the other NEPB laboratories—remain at the 
Temple of Heaven and Heaven only knows what is in store there for the future.”91 
Tang Feifan, Tong Cun, and other researchers did stay in China after the 1949 
establishment of the People’s Republic of China, although the Nationalist regime they served 
did not. The NEPB was renamed the Beijing Vaccine and Serum Institute and continued to 
oversee the national production of a variety of biological products. The production of 
penicillin had likely helped consolidate the NEPB’s authority over the production of 
biologicals of a therapeutic, as well as preventive, nature. Tang continued to work there, 
although resuming his prewar research on trachoma, an eye disease widespread in China 
during the Republican period. Tang is largely remembered worldwide as the first scientist to 
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successfully identify the cause of trachoma in 1957, when he identified, isolated, and 
cultivated the bacterium Chlamydia trachomatis.92 He tragically passed away shortly 
thereafter. Fan Qingsheng, too, won acclaim as a specialist in agricultural microbiology, 
especially in promoting the cultivation of edible and medicinal mushrooms in China, and he 
enjoyed an illustrious teaching career in Nanjing.93 Despite his fear of being blamed for 
failing to complete an impossible task in transferring a pilot plant from the United States, 
Tong Cun is memorialized in contemporary accounts as having “established the foundation of 
the antibiotic enterprise” in China. After the establishment of the People’s Republic, Tong 
worked in a variety of pharmaceutical manufacturing units in Shanghai, ultimately enjoying a 
long career at the intersection of academia and industry.94  
 
Conclusion 
It is easy, and tempting, to read the narrative of Tang Feifan and his colleagues at the 
NEPB as one of unqualified success: of a ragtag team of researchers in desperate conditions 
of war, relying on their wits and ingenuity to produce a lifesaving drug despite the naysaying 
of wealthy and powerful American colleagues. Yet to do so would unfairly overlook the 
extent of the efforts of ABMAC personnel and somewhat overstate the impact of the NEPB’s 
work. The technologies, texts, and human resources necessary for penicillin manufacture 
traveled to China in many different forms, at many different times: through the Lend-Lease 
Act, through the long travels of Tong Cun, even in the shipment of the latest edition of the 
Lancet to a remote laboratory at the fringes of the Chinese polity. Yet the first successful 
production of the drug did happen in Kunming at the NEPB, and it did happen amid the 
wartime conditions of scarcity and calamity that had come to describe everyday life for 
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millions of people in China’s interior. 
Amid technical debates over scientific possibility and efforts to find Chinese 
substitutes for American materials, the case files of the first patients in wartime China who 
were actually treated with penicillin stand out. This article has discussed some ramifications 
of the terms of everyday life in wartime China for a small and elite group of medical 
researchers, both as they experienced it and as American philanthropists perceived it, but the 
advent of penicillin promised to change the terms of everyday life for almost everyone in 
China. It made formerly fatal conditions like gonorrhea or hospital infections survivable. We 
do not have easy access to their perspectives in surviving records, but the range of patients—
male and female, young and old—who were the experimental subjects of the first therapeutic 
use of penicillin in China represent the first group of individuals who experienced this new 
version of what would quickly become normal medical practice. 
Questions of the “normal” in biomedical research and development are more relevant 
than ever when it comes to the production of antibiotics. After the economic reforms of the 
1980s that incentivized the sales of medicines by tying them to doctors’ salary scales, 
physicians in China inadvertently systematically overprescribed penicillin and other 
antibacterial drugs. Global pharmaceutical firms’ heavy promotion of antibiotics, as well as 
the widespread regular use of tetracycline and related drugs in fisheries and livestock 
management, contributed to the proliferation of antibiotic-resistant bacteria in the 
environment. Although recent reforms have made Chinese physicians’ pay totally 
independent of their prescribing habits and prohibited over-the-counter sales of antibiotics, 
bacteria that are resistant to treatment with antibiotics remain a major public health threat, in 
China and around the world.95 The history of the development of penicillin in China provides 
                                                
95 Hvistendahl, “China Takes Aim,” 795. 
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a timely reminder, then, of the fragility, difficulty, and historical contingency of their 
development. 
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